Bottom line
XLV vs HIAHX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and HIAHX (Hartford Healthcare Hls Fund) share a meaningful slice of their top holdings — about 72% by weight.
XLV is cheaper at 0.08% vs 0.94% — a difference of $86 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +3.5% for HIAHX.
Updated Nov 19, 2026
XLV vs HIAHX side by side
| XLV | HIAHX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Hartford |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.94% |
| Annual cost per $10k | $8 | $94 |
| 10-yr cost on $10k (prospectus) | $103 | $1,155 |
| Max front load | None | — |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +16.1% |
| 5-yr return (annualized) | +8.1% | +3.5% |
| 10-yr return (annualized) | +9.8% | +7.9% |
| Best quarter | +14.5% | +21.0% |
| Worst quarter | −12.7% | −15.6% |
| Net assets (fund) | $40.6B | $112.4M |
| Number of holdings | 65 | 79 |
| Portfolio turnover | 2% | 5% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | HIAHX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +16.1% | −1.6% |
| 2024 | +2.5% | +0.4% | +2.1% |
| 2023 | +2.0% | +4.1% | −2.1% |
| 2022 | −2.1% | −11.2% | +9.2% |
| 2021 | +25.9% | +10.0% | +15.9% |
| 2020 | +13.3% | +23.1% | −9.8% |
| 2019 | +20.7% | +34.0% | −13.3% |
| 2018 | +6.3% | −2.7% | +9.0% |
| 2017 | +21.7% | +22.3% | −0.6% |
| 2016 | −2.8% | −8.4% | +5.6% |
Source: Fund prospectus bar charts
Holdings overlap
19 of XLV's top 25 holdings also appear in HIAHX's top 25.
| Holding | XLV | HIAHX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 12.47% |
| Johnson & Johnson | 10.64% | 6.63% |
| AbbVie Inc | 7.74% | 3.43% |
| UnitedHealth Group Inc | 6.57% | 4.72% |
| Merck & Co Inc | 5.52% | 6.60% |
| Thermo Fisher Scientific Inc | 3.24% | 1.64% |
| Abbott Laboratories | 2.75% | 2.10% |
| Intuitive Surgical Inc | 2.45% | 2.99% |
| CVS Health Corp | 2.30% | 2.93% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.69% |
| Danaher Corp | 2.09% | 2.65% |
| Stryker Corp | 1.89% | 1.17% |
| Medtronic PLC | 1.75% | 1.02% |
| Elevance Health Inc | 1.46% | 2.96% |
| Boston Scientific Corp | 1.10% | 1.19% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
HIAHX top 10
- Eli Lilly & Co — 12.47%
- Johnson & Johnson — 6.63%
- Merck & Co Inc — 6.60%
- UnitedHealth Group Inc — 4.72%
- AbbVie Inc — 3.43%
- Intuitive Surgical Inc — 2.99%
- Elevance Health Inc — 2.96%
- CVS Health Corp — 2.93%
- Vertex Pharmaceuticals Inc — 2.69%
- Danaher Corp — 2.65%
FAQ
What is the difference between XLV and HIAHX?
Which is cheaper, XLV or HIAHX?
Should I own both XLV and HIAHX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.